Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
99 hedge funds and large institutions have $86.3M invested in Evofem Biosciences, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 36 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 25
11% less call options, than puts
Call options by funds: $1.1M | Put options by funds: $1.24M
19% less funds holding
Funds holding: 122 → 99 (-23)
27% less capital invested
Capital invested by funds: $119M → $86.3M (-$32.4M)
58% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.69M |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$2.38M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.52M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$6.67M |
| 2 |
Morgan Stanley
New York
|
-$6.6M |
| 3 |
Millennium Management
New York
|
-$5.1M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
-$4.5M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$2.87M |
EVFM Hedge Fund Activity: Q3 2020 in Review
99 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2020, worth a combined $86.3M — down 27% from $119M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of EVFM and 15 opened new positions — a net loss of 21 holders — while 25 trimmed existing stakes and 37 added.
The largest buyer was BlackRock, adding an estimated $6.14M. The largest seller was Marshall Wace, exiting entirely with an estimated $6.67M sold.
- 99 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2020, down from 122 in Q2 2020.
- Funds reported $86.3M of Evofem Biosciences, Inc. Common Stock stock for Q3 2020, down 27% quarter-over-quarter.
- 15 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2020 and 36 closed out, a net change of -21 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2020 was BlackRock, an estimated $6.14M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2020 was Marshall Wace, an estimated $6.67M sold.
Based on aggregated 13F filings for Q3 2020.